The Immunotherapy Series, Part Three: Policy and the FDA
Immunotherapy and Policy. How can the FDA evolve to help advance and support novel approaches to medicine? How does the field of immune-driven diagnostics serve as a case in point for the need for evolution in existing regulatory frameworks?
Chief Executive Officer
Assistant Professor, Department of Immuno-Oncology
Assistant Professor, Department of Pediatrics
City Of Hope
This series is brought to you ad-free by Adaptive Biotechnologies